Impaired glucose tolerance: Is there a case for pharmacologic intervention?

Treatments in Endocrinology

Volumn 1, Issue 4, 2002, Pages 205-210

  Costa, Àngels ^a   Conget, Ignacio ^a,b   Gomis, Ramon ^a  

^a HOSPITAL CLÍNIC   (Spain)

^b UNIVERSITY OF BARCELONA   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

ACARBOSE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; METFORMIN; TRIACYLGLYCEROL;

CARDIOVASCULAR DISEASE; CARDIOVASCULAR RISK; DIET THERAPY; DISEASE COURSE; DRUG EFFICACY; EXERCISE; GLUCOSE BLOOD LEVEL; HUMAN; HYPERCHOLESTEROLEMIA; HYPERTENSION; HYPERTRIGLYCERIDEMIA; IMPAIRED GLUCOSE TOLERANCE; INSULIN RESISTANCE; LIFESTYLE; NON INSULIN DEPENDENT DIABETES MELLITUS; OBESITY; ORAL GLUCOSE TOLERANCE TEST; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW;

DIABETES MELLITUS, TYPE 2; GLUCOSE INTOLERANCE; HUMANS; HYPOGLYCEMIC AGENTS; RISK REDUCTION BEHAVIOR; WEIGHT LOSS;

EID: 0037669866     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200201040-00001     Document Type: Review

References (44)

1. The DECODE study group. Glucose tolerance and mortality: comparison of WHO and American Diabetes Association diagnostic criteria. Lancet 1999; 354: 617-21
2. Bonora E, Kiechl S, Oberhollenzer F, et al. Impaired glucose tolerance, type II diabetes mellitus and carotid atherosclerosis: prospective results from the Bruneck Study. Diabetologia 2000; 43: 156-64
3. Tuomilehto J, Lindström J, Eriksson JG, et al. Prevention of type 2 diabetes mellitus by changes in lifestyle among subjects with impaired glucose tolerance. N Engl J Med 2001; 344: 1343-50
4. The Diabetes Prevention Program Research Group. Reduction in the incidence of type 2 diabetes with lifestyle intervention of metformin. N Engl J Med 2002; 346: 393-403
5. Chiasson JL, Josse RG, Gomis R, et al. Acarbose for prevention of type 2 diabetes mellitus: the STOP-NIDDM randomised trial. Lancet 2002 Jun 15; 359 (9323): 2072-7
6. National Diabetes Data Group. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 1979; 28: 1039-57
7. World Health Organization. Second report of the WHO expert committee on diabetes mellitus. Geneva: WHO, 1980. Technical Report Series 646
8. Alberti KGMM, Zimmet PZ, for the WHO Consultation. Definition, diagnosis and classification of diabetes mellitus and its complications. Part I: diagnosis and classification of diabetes mellitus. Provisional report of a WHO consultation. Diabet Med 1998; 15: 539-53
9. Saad MF, Knowler WC, Pettitt DJ, et al. Transient impaired glucose tolerance in Pima Indians: is it important? BMJ 1988; 297: 1438-41
10. King H, Rewers M, for the WHO Ad Hoc Diabetes Reporting Group. Global estimates for prevalence of diabetes mellitus and impaired glucose tolerance in adults. Diabetes Care 1993; 16: 157-77
11. Harris MI. Impaired glucose tolerance: prevalence and conversion to NIDDM. Diabet Med 1996; 13 Suppl. 2: S9-S11
12. Heine RJ, Nijpels G, Mooy JM. New data on the rate of progression of impaired glucose tolerance to NIDDM and predicting factors. Diabet Med 1996; 13 (2 Suppl. 3): S12-4
13. Reaven GM, Hollenbeck CB, Chen YD. Ralationship between glucose tolerance, insulin secretion, and insulin action in non-obese individuals with varying degrees of glucose intolerance. Diabetologia 1989: 32: 52-5
14. Byrne MM, Sturis J, Sobel RJ, et al. Elevated plasma glucose 2-h post-challenge predicts defects in β-cell function. Am J Physiol 1996; 270: E572-9
15. Lillioja S, Mott DM, Howard BV, et al. Impaired glucose tolerance as a disorder of insulin action: longitudinal and cross-sectional studies in Pima Indians. N Engl J Med 1988; 318: 1217-25
16. Walker M, Berrish TS, Stewart MW, et al. Metabolic heterogeneity in impaired glucose tolerance [abstract]. Diabetologia 1995; 38 Suppl. 1: A11
17. Pratley RE, Weyer C. The role of impaired early insulin secretion in the pathogenesis of type II diabetes mellitus. Diabetologia 2001; 44: 929-45
18. Reaven GM. Role of insulin resistance in human disease. Diabetes 1988; 37: 1595-607
19. Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000 Aug 12; 321 (7258): 405-12
20. American Diabetes Association. Postprandial blood glucose. Diabetes Care 2001; 24: 775-8
21. Hanefeld M, Fischer S, Julius U, et al. Risk factors for myocardial infarction and death in newly detected NIDDM: the Diabetes Intervention Study, I 1-year follow-up. Diabetologia 1996; 39: 1577-83
22. The DECODE study group on behalf of the European Diabetes Epidemiology Group. Glucose tolerance and cardiovascular mortality comparison of fasting and 2-h diagnostic criteria. Arch Intern Med 2001; 161: 397-404
23. Sievers ML, Bennett P, Nelson RG. Effect of glycemia on mortality in Pima Indians with type 2 diabetes. Diabetes 1999; 48: 896-902
24. Ceriello A, Bortolotti N, Motz E, et al. Meal-generated oxidative stress in type 2 diabetic patients. Diabetes Care 1998; 21: 1529-33
25. Gopaul NK, Manraj MD, Hebe A, et al. Oxidative stress precede endothelial dysfunction and insulin resistance in Indian Mauritians with impaired glucose metabolism. Diabetologia 2001; 44: 706-12
26. Tomiyama H, Kimura Y, Okazaki R, et al. Close relationship of abnormal glucose tolerance with endothelial dysfunction in hypertension. Hypertension 2000; 36: 245-9
27. Fernandez-Real JM, Vendrell J, Ricart W, et al. Polymorphism of the tumour necrosis factor-alpha receptor 2 gene is associated with obesity, leptin levels, and insulin resistance in young subjects and diet-treated type 2 diabetic patients. Diabetes Care 2000; 23: 831-7
28. McGarry JD. What if Minkowski had been ageusic?: an alternative angle on diabetes. Science 1992; 258: 766-70
29. Ceriello A, Motz E, Cavarape A, et al. Hyperglycemia counterbalances the antihypertensive effect of glutathione in diabetic patients: evidence linking hypertension and glycemia through the oxidative stress in diabetes mellitus. J Diabetes Complications 1997: 11: 250-5
30. Cerielo A, Toboga C, Tonutti L, et al. Pot-meal coagulation activation in diabetes mellitus: the effect of acarbose. Diabetologia 1996; 39: 469-73
31. Cerielo A, Falleti E, Bortolotti N, et al. Increased circulating intercellular adhesion molecule-1 levels in type-II diabetic patiens: the possible role of the oxidative stress and metabolic control. Metabolism 1996; 45 Suppl. 1: 498-501
32. Ferranini E. Insulin resistance versus insulin deficiency in non-insulin-dependent diabetes mellitus: problems and prospects. Endocr Rev 1998; 19: 477-90
33. Pan XR, Li GW, Hu YH, et al. Effects of diet and exercise in preventing NIDDM in people with impaired glucose tolerance. Diabetes Care 1997; 20: 537-44
34. Savage PJ, Bennion LJ, Flock EV, et al. Diet-induced improvement of anormalities in insulin and glucagon secretion and in insulin receptor binding in diabetes mellitus. J Clin Endocrinol Metab 1979; 48: 999-1007
35. Marshall JA, Hoag S, Shetterly S, et al. Dietary fat predics conversion from impaired glucose tolerance to NIDDM. Diabetes Care 1994; 17: 50-6
36. Björntorp P, de Jounge K, Sjöström L, et al. Physical training in human obesity: effects of plasma insulin in glucose-intolerant subjects without marked hyperinsulinemia. Scand J Clin Lab Invest 1973; 32: 41-5
37. Azen SP, Peters RK, Berkowitz K, et al. The Troglitazone in the Prevention of Diabetes (TRIPOD) study assessed the effect of troglitazone on the incidence of type 2 diabetes mellitus in women with recent gestational diabetes. Control Clin Trials 1998; 19: 217-31
38. Buchanan TA, Xiang AH, Peters RK, et al. The TRIPOD Study: preservation of pancreatic B -cell function and prevention of type 2 diabetes by pharmacological treatment of insulin resistance in high-risk Hispanic women. Diabetes. In press
39. Heart Outcome Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO HOPE substudy. Lancet 2000; 255: 253-9
40. Heymsfield SB, Segal KR, Hauptman J, et al. Effects of weight loss with Orlistat on glucose tolerance and progression to type 2 diabetes in obese adults. Arch Intern Med 2000; 160: 1321-6
41. Sheperd J, Cobbe SM, Ford I, et al. West of Scotland Coronary Prevention Study Group. Prevention of coronary heart disease with pravastatin in men with hypercholesterolemia. N Engl J Med 1995; 333: 1301-7
42. Torgerson JS, Arlinger K, Kappi M, et al. Principles for enhanced recruitment of subjects in a large clinical trial: the XENDOS (XENical in the prevention of Diabetes in Obese Subjects) study experience. Control Clin Trials 2001; 22: 515-25
43. Shepherd J, Blauw GJ, Murphy MB, et al. The design of a prospective study of pravastatin in the elderly at risk (PROSPER). Am J Cardiol 1999; 84: 1192-7
44. Wadden TA, Sternberg JA, Letizia KA, et al. Treatment of obesity by very low calorie diet, behavior therapy, and their combination: a five-year perspective. Int J Obes 1989; 13 Suppl. 2: 39-46